MARIA VALDEZ: Open Payments
NPI 1982704565 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,490 in 56 payments from 29 companies in 2025. Trend: 2023 $1,297 · 2024 $2,398 · 2025 $2,490
Food & beverage: $1,309Long term medical supply or device loan: $1,000Education: $181
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $1,021 |
| AstraZeneca Pharmaceuticals LP | 3 | $242 |
| JAZZ PHARMACEUTICALS INC. | 2 | $143 |
| Tempus AI, Inc | 1 | $126 |
| Janssen Biotech, Inc. | 6 | $104 |
| SEAGEN INC. | 1 | $93 |
| Incyte Corporation | 1 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $84 |
| Merck Sharp & Dohme LLC | 3 | $67 |
| Daiichi Sankyo Inc. | 2 | $53 |
Products named: KISQALI, ZEPZELCA, LYNPARZA, XT CDX, IMFINZI, FRUZAQLA, KEYTRUDA, Enhertu.
Industry payments across TX — which companies pay providers there.
